Action Plan to Address the Epidemic of
Stealth Virus Associated Illnesses

Once the existence of stealth-adapted viruses becomes reluctantly accepted by Public Health officials, they will be asked to respond to the obvious question: “What can we do to prevent these infections and how should they be diagnosed and treated.” The following information may be helpful in formulating appropriate answers:

 

1. Case studies indicate that stealth-adapted viruses can readily pass between individuals through casual as well as sexual contacts. Examples of community wide disease outbreaks have been reported to CDC and need to be re-examined as potential stealth virus epidemics.
2. Infected individuals pose a potential threat to others. Good hygiene needs to be encouraged in medical offices, hospitals, classrooms for children with special educational needs, meeting places, households with an infected family member, etc. Long acting disinfectants are to be preferred over short acting oxidizing agents such as bleach.
3. Childhood vaccinations, as well as live virus vaccines administered to infected adults appear capable of potentiating stealth virus infections. Children born of stealth virus infected mothers should probably be exempted from childhood vaccination programs. Stealth virus infected children should also be given special training, preferably by their parents, to help overcome the tendency to lose cognitive functions, such as is seen with children with autism.
4. Preexisting antibodies reactive with a stealth virus can probably provide a barrier to brain infection. The potential use of a cross reactive vaccine needs to be explored in well defined clinical studies. Note that the antibody response to many viruses can be directed against many more viral components than is typically the cellular immune response.
5. The best screening method for stealth-adapted viruses is undoubtedly viral cultures. Back up systems, including the polymerase chain reaction (PCR) and micro-arrays can also be developed. Not all stealth virus isolates can be readily detected using molecular assays.
6. Unusual bacteria and fungi cultured from stealth virus infected patients need to be examined for evidence of stealth viruses. The terms viteria and vifungus were introduced to describe stealth viruses that had acquired bacteria-derived and fungal-derived genetic sequences, respectively.
7. Define the pathogenic mechanisms operating in stealth virus infected cells, including the functional role of assimilated cellular and bacteria-derived genes, alternative cellular energy pigments, etc.
8. The major focus on therapy should be directed towards: i) Promoting the capacity of cells to derive energy through an alternative (non-mitochondria) cellular energy pathway. This can be achieved in part using various natural products of value in plant growth. Various biophysics based therapies should also be evaluated, including the use of experimentally inoculated animals. ii) Enhance mitochondria function, including reducing levels of oxidative stress. iii) Suppress cytokine/chemokine stimulation of virus activity. iv) Reduce the load of any conventional viruses that may be activating the stealth viruses. Each of these approaches needs to be subjected to well defined clinical trials.
9. Resolve the issue of whether the use of cytomegalovirus contaminated polio vaccines in Africa led to the formation of HIV. The testing of sera collected in 1958/1959 from polio vaccine immunized African children for the formation of anti-cytomegalovirus antibodies would be informative.
10. Review the actions of Public Health officials who were responsible for delaying addressing the issue of stealth-adapted viruses so that an example may be in place to avoid repeating a comparable error in the future.